Trofinetide

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.

Potential Rett syndrome drug shows promising results in phase 3 trial

A potential first-of-its-kind drug to treat the symptoms of Rett syndrome received positive top-line results from a phase 3 trial led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety.